KP1077 Shows Promise as Potential Treatment for Idiopathic Insomnia in Phase 2 Trial
Data from a phase 2, double-blind, placebo-controlled, randomized-withdrawal, dose-optimizing trial (NCT05668754) showed that KP1077 (Zevra Therapeutics), an investigational agent, was well tolerated in patients with idiopathic hypersomnia (IH), with …